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Papillomavirus 16 DNA upon Beta Interferon Stimulation
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Masamichi Muramatsua
‹Department of Molecular Genetics, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japana; Pathogen Genomics Center, National Institute of
Infectious Diseases, Musashimurayama, Tokyo, Japanb
Apolipoprotein BmRNA-editing catalytic polypeptide 3 (APOBEC3) proteins are interferon (IFN)-inducible antiviral factors
that counteract various viruses such as hepatitis B virus (HBV) and human immunodeficiency virus type 1 (HIV-1) by inducing
cytidine (C)-to-uracil (U) mutations in viral DNA and inhibiting reverse transcription. However, whether APOBEC3 proteins
(A3s) can hypermutate human papillomavirus (HPV) viral DNA and exhibit antiviral activity in human keratinocyte remains
unknown. Here we examined the involvement of A3s in the HPV life cycle using cervical keratinocyteW12 cells, which are de-
rived from low-grade lesions and retain episomal HPV16 genomes in their nuclei. We focused on the viral E2 gene as a potential
target for A3-mediated hypermutation because this gene is frequently found as a boundary sequence in integrated viral DNA.
Treatment ofW12 cells with beta interferon (IFN-) increased expression levels of A3s such as A3A, A3F, and A3G and induced
C-to-U conversions in the E2 gene in a manner depending on inhibition of uracil DNA glycosylase. Exogenous expression of A3A
and A3G also induced E2 hypermutation inW12 cells. IFN--induced hypermutation was blocked by transfection of small inter-
fering RNAs against A3G (andmodestly by those against A3A). However, the HPV16 episome level was not affected by overex-
pression of A3A and A3G inW12 cells. This study demonstrates that endogenous A3s upregulated by IFN- induce E2 hypermu-
tation of HPV16 in cervical keratinocytes, and a pathogenic consequence of E2 hypermutation is discussed.
Apolipoprotein B mRNA-editing catalytic polypeptide (APOBEC)proteins are a family of proteins that share cytidine deaminase
activity of DNA and RNA. In humans, the APOBEC family is
composed of at least 11 members, including activation-induced
cytidine deaminase (AID) and APOBEC1, -2, -3A, -3B, -3C, -3DE,
-3F, -3G, -3H, and -4 (1, 2). AID introduces cytidine (C)-to-uracil
(U) conversion in immunoglobulin (Ig) genes, a step that is fur-
ther catalyzed by downstream DNA repair machineries, including
base excision repair (BER), mismatch repair, and nonhomolo-
gous end-joining repair, to trigger somatic hypermutation, class
switch recombination, gene conversion, and chromosomal trans-
location (3–6). AID also introduces mutations in non-Ig gene loci,
such as c-Myc and Bcl-6, although less frequently than in Ig genes
(3, 7). Recent studies have suggested that APOBEC3 protein (A3)
deaminase activity is responsible for a novel type of mutations
called kataegis in multiple human cancers, including cancers of
the bladder, cervix, lung, head and neck, and breast (8–13).
A3s are antiviral factors against viruses and transposable ele-
ments that use reverse transcription during their life cycle (1, 2,
14–16). The antiviral functions of A3s have been extensively stud-
ied for human immunodeficiency virus type 1 (HIV-1) and hep-
atitis B virus (HBV). APOBEC3G (A3G) physically associates with
viral RNP complexes, including viral genomic RNA, gag protein
(in the case of HIV-1), and P and core protein (in the case of
HBV), and is encapsidated into a nucleocapsid, thereby inhibiting
reverse transcription in infected cells (2, 14, 17). Moreover, A3G-
induced hypermutation in viral DNA leads to inhibition of HIV-1
replication by either BER-mediated DNA degradation or accumu-
lation of destructive mutations in the viral genome (16, 18–20).
How C-to-U conversion in cellular or viral DNA is converted into
different genetic alterations (hypermutation, recombination, and
DNA degradation) remains unknown.
Human papillomaviruses (HPVs) are small double-stranded
DNA viruses infecting epithelial cells. A subset of mucosal HPVs is
recognized as a causative agent of cervical cancer (21, 22), among
which HPV16 accounts for at least 50% of cervical cancer cases
worldwide (23). The HPV16 genome is a 7.9-kb closed circular
DNA and is composed of at least 8 open reading frames (E1, E2,
E4, E5, E6, E7, L1, and L2) as well as the noncoding long control
region (LCR). LCR contains the replication origin and the P97
promoter responsible for transcription of the E6 and E7 genes. E6
and E7 are viral oncoproteins that degrade p53 and retinoblas-
toma proteins, respectively, and their enhanced expression is re-
quired for cellular transformation (22). In its normal life cycle,
HPV16 infects the basal cells of cervical epithelia and establishes
their genomes as extrachromosomal episomes. In invasive cervical
cancer, however, the viral DNA is frequently integrated into the
host chromosome, which generally leads to constitutive expres-
sion of E6 and E7. The viral DNA integration often results in
disruption of the E2 gene and loss of E2 expression. This disrup-
tion of the E2 gene causes upregulation of E6/E7 expression be-
cause E2 is a transcriptional repressor of the P97 promoter respon-
sible for E6/E7 expression. Although viral DNA integration is an
important step in HPV-induced carcinogenesis (24, 25), a mech-
anism of HPV integration remains unknown.
A3s can also target DNA viruses that do not use reverse tran-
scription in their replication cycle, including TT virus, adeno-
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associated virus (AAV), herpes simplex virus 1 (HSV-1), and Ep-
stein-Barr virus (26–30). To date, only a single study of A3-
mediated hypermutation in HPV has been reported (31), in which
Vartanian et al. detected hypermutation in the LCR of the HPV16
DNA isolated from clinical specimens of cervical precancerous
lesions. They further demonstrated the LCR hypermutation in
HPV1a DNA isolated from 293T cells transfected with an HPV
plasmid and A3 expression vectors. However, Stenglein et al. re-
cently demonstrated that transfected plasmids were hypermu-
tated in the presence of overexpressed A3s except A3G (32), rais-
ing a concern about whether the observed hypermutation in the
transfected HPV DNA truly reflects HPV pathophysiology.
In this study, we utilized cervical keratinocyte W12 cells that
are derived from low-grade cervical intraepithelial lesions caused
by natural infection of HPV16 and represent a unique model sys-
tem for studying early events in HPV persistent infection (33, 34).
Using the W12 system, we investigated whether A3s induce hyper-
mutation in HPV16 DNA and exhibit antiviral activity against
HPV16.
MATERIALS AND METHODS
Reagents and cell culturing.Beta interferon (IFN-) and tamoxifen were
purchased from Daiichi Sankyo and Wako, respectively. W12 (20863
clone) cells were maintained as reported previously (33, 35). In brief, W12
cells were cocultured with mitomycin C-treated 3T3 feeder cells in F me-
dium composed of 3 parts F-12 medium and 1 part Dulbecco’s modified
Eagle’s medium supplemented with 5% fetal bovine serum, 5 g/ml of
insulin, 8.4 ng/ml of cholera toxin, 24 g/ml of adenine, 10 ng/ml of
epidermal growth factor, 0.4 g/ml of hydrocortisone, and 100 U/ml
penicillin, and 100 mg/ml streptomycin. W12 cells were infected with
UNG inhibitor-estrogen receptor (UGI-ER)-expressing retroviruses, and
transduced cells were further selected by puromycin (36, 37) using puro-
mycin-resistant feeder cells. Plasmids were transfected into W12 cells us-
ing Fugene 6 (Roche), according to the manufacturer’s instructions. All
small interfering RNAs (siRNAs) were purchased from Invitrogen and
were transfected into W12 cells using Lipofectamine 2000 (Invitrogen),
according to the manufacturer’s instructions.
Plasmids. A mock-estrogen receptor (mock-ER) expression vector
was made by replacing the AID gene in pCMV-AID-ER (38) with linker
DNA containing an in-frame ATG. This vector expresses a 36-kDa
mock-ER protein. Human A3A- and A3G-ER expression vectors were
made by replacing the AID gene in pCMV-AID-ER with the A3A and A3G
genes in frame. DNA fragments encoding human A3A and A3F were
generated by reverse transcription-PCR (RT-PCR) using primers A3A
fwd, 5=-ATAGAATTCATGGAAGCCAGCCCAGC-3=, A3A rev, 5=-ATAT
CTCGAGTCAGTTCCCTGATTCT-3=, A3F fwd, 5=-ATTTAAGCTTATG
AAGCCTCACTTCAG-3=, and A3F rev, 5=-AATTCTCGAGTCATTCGA
GAATCTCCTGCAG-3=, and inserted into a multiple cloning site of
pcDNA3Tag1A (Invitrogen) to make FLAG-tagged A3A and A3F expres-
sion vectors, respectively. The A3G nontagged protein expression vector
was made by deletion of FLAG region from pFlag-A3G (37). Differential
DNA denaturation PCR (3D-PCR) control vectors were generated by
cloning PCR fragments into the pGEM-T Easy vector (Promega). Briefly,
the E2 PCR fragments were amplified with #888 and #843 E2 primers
(Table 1) from total DNA isolated from W12 cells using a 3D-PCR pro-
tocol. Plasmids which contain no mutations (negative control [n.c.]), 4
C-to-T mutations (4 positive control [p.c.]), or 26 C-to-T mutations
(26 p.c.) were used as controls. Control DNAs for LCR and TP53 3D-
PCR were also generated using primers described elsewhere (31, 39). All
the plasmids used in this study were sequenced at least once to verify them.
Other plasmids used in this study have been described previously (37, 40).
Detection of hypermutation in E2, LCR, and TP53. Total DNA was
extracted by a standard method. In brief, cells were digested with buffer
containing 200g/ml proteinase K, 1% (vol/vol) sodium dodecyl sulfate,
150 mM NaCl, 25 mM EDTA, and 50 mM Tris-HCl (pH 8.0) at 55°C
overnight. Total DNA was purified by phenol-chloroform extraction,
treated with RNase A to remove RNA, and further purified by phenol-
chloroform extraction and ethanol precipitation. E2 3D-PCR was per-
formed by modification of a previously published method (41, 42). The
initial PCR was performed as follows: 94°C for 4 min, followed by 35
cycles, each at 94°C for 16 s, 55°C for 20 s, and 68°C for 50 s, and a final
elongation step at 65°C for 10 min, using #908 and #845 primers (Table 1).
Nested PCR was performed as follows: 86.9 to 82.6°C for 5 min, followed
by 35 cycles, each at 86.9 to 82.6°C for 45 s, 50°C for 30 s, and 65°C for 38
s, and a final elongation step at 65°C for 10 min, using #888 and #843
primers, on a MasterCycler Pro thermal cycler (Eppendorf). The nested
PCR amplified an E2 gene fragment (nucleotide number 3400-3564) in
HPV genomic DNA (GenBank accession number AF125673). LCR and
TP53 3D-PCR were performed as described previously (31, 39), with mi-
nor modifications. rTaq (TaKaRa) was used for PCRs for both 3D-PCR
and estimation of mutation load, because high-fidelity DNA polymerase
cannot amplify uracilated DNA. To determine the hypermutation fre-
quency, PCR fragments from 3D-PCR or standard PCR (94°C denatur-
ation) were cloned into a T vector, and the indicated number of successful
recombinant clones were selected randomly and sequenced using an ABI
Prism 3130 (Applied Biosystems). The W12 HPV16 sequence (GenBank
accession number AF125673) was used as a reference sequence to examine
the presence of mutations.
RT-qPCR. cDNAs were prepared as reported previously (37, 40). In
brief, total RNA was extracted and treated with DNase I to digest genomic
DNA. For reverse transcription-quantitative PCR (RT-qPCR) analysis,
total RNA was again treated with amplification-grade DNase I (Invitro-
gen) and reverse transcribed using SuperScript III (Invitrogen). The
cDNA was amplified using specific primers for A3A, A3B, A3C, A3DE,
A3F, A3G, A3H, AID, APOBEC1 (A1), and hypoxanthine phosphoribo-
syltransferase (HPRT) (37, 40). To calculate relative A3 expression levels,
serially diluted plasmids containing each A3 gene were used to form a
standard curve. Expression of HPRT was used to normalize expression
levels of A3s under different culture conditions. RT-PCR analysis to de-
termine ISG54 expression were performed with primers 5=-GAGAACTG
CAATGTTTCAGGACC-3= and 5=-TGTATAGTTGTTTGCAGCTGTGT
GC-3=. ISG56 primers have been shown previously (43).
Southern blotting and Western blotting. DNA probes spanning the
entire HPV16 viral genome (GenBank accession number NC_001526)
were generated by PCR using primer pairs #765/836 and #928/1111 (Table
2). A DNA probe that recognizes a human genomic locus (AICDA) was
generated by PCR primer pairs #1124/1165 (Table 2) and used to deter-
mine the amount of DNA loaded per gel in Southern blotting. Probe
labeling and signal development were performed using the AlkPhos direct
labeling system (Amersham), and the signals were detected using the
LAS1000 imager system (FujiFilm). Western blotting was performed us-
ing a standard method as described previously (37, 40). The antibodies
used in this study were as follows: rabbit anti-A3G (37), rabbit anti-
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (G9545; Sigma),
rabbit anti-ER (HC-20; Santa Cruz), anti-rabbit IgG-horseradish peroxi-
dase (HRP) (ALI3404; eBioscience), mouse anti-FLAG (M2; Sigma), anti-
mouse IgG-HRP (GE Healthcare), and anti-HA (ab-HAtag; InvivoGen).
UNG assay. A uracil DNA glycosylase (UNG) assay was performed as
described previously (37, 44).
TABLE 1 3D-PCR assay primer list
Primera Sequence (5=3=)
First F (#908) ATGGGAAGTTCATGCGGGTGGTCA
First R (#845) TGGGTGTAGTGTTACTATTACAGTTAAT
Second F (#843) TCCTGAAATTATTAGGCAGCACTT
Second R (#888) CGTCCTTTGTGTGAGCTGTTAAAT
a F, forward; R, reverse.
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Statistical analysis. Statistical analyses were performed using Graph-
Pad Prism (GraphPad software). Analysis of variance (ANOVA) was used
for RT-qPCR data. Pearson’s chi-square test was used for mutation anal-
yses. P values of less than 0.05 between experimental groups were consid-
ered statistically significant. For all graphs in this study, error bars indicate
the standard errors of the means from triplicate samples.
RESULTS
Induction of APOBEC3 genes by IFN- stimulation. One of the
type I IFNs, IFN-, has been shown to repress HPV DNA replica-
tion in keratinocyte cell lines, including W12 cells (35, 45, 46).
Because A3s are IFN-inducible antiviral factors against retrovi-
ruses and HBV (1, 2, 14, 16, 37), we aimed to explore the involve-
ment of A3s in the IFN- action against HPV. We first examined
basal expression levels of each A3 gene in W12 cells. RT-qPCR
analysis showed that all seven A3s were expressed at different lev-
els: A3C and A3G were the highest; A3A, A3DE, and A3H were
intermediate; and the lowest were A3B and A3F (Fig. 1A). We then
examined which A3 member is induced upon IFN- treatment in
W12 cells. RT-qPCR revealed that IFN- treatment upregulated
mRNA levels of most A3s, including A3A, A3F, and A3G, in W12
cells (Fig. 1B). Increased expression of A3G protein by IFN-was
also confirmed by Western blotting (Fig. 1C). However, available
antibodies did not detect endogenous A3A protein in IFN- stim-
ulated W12 cells (data not shown). Putative type I IFN-responsive
genes IFN-stimulated gene 54 (ISG54) and ISG56 (also known as
IFIT2 and IFIT1, respectively) (47) were also upregulated (Fig.
1D), suggesting that a signaling pathway of IFN- is operative in
W12 cells. Other APOBEC family members APOBEC1 and AID
were not expressed in the IFN--stimulated and nonstimulated
W12 cells (Fig. 1A).
APOBEC3A and -3Ghypermutate theHPV16 E2 gene. In the
case of HBV infection, expression of A3s in the infected hepato-
cytes, either by overexpression of these proteins or through IFN
stimulation, leads to hypermutation of viral DNA (2, 16, 37, 40,
42, 48, 49). We investigated whether A3s can hypermutate HPV16
DNA. To this end, we evaluated the effects of A3A, A3F, and A3G
because expression of these A3s is induced by IFN- stimulation
in W12 cells (Fig. 1B). First, we simply overexpressed A3A, A3F,
and A3G in W12 cells. HPV16 LCR DNA from these cells was
cloned into a T vector, and 10 clones were sequenced; however, we
did not see any sign of hypermutation (data not shown).
Then we applied 3D-PCR assay that can detect hypermutated
DNA with higher detection sensitivity by decreasing the denatur-
ation temperature in a PCR. Since Vartanian et al. (31) reported
hypermutation in the LCR of HPV genomes by 3D-PCR assay, we
chose the same region, using total DNA isolated from A3A- and
A3G-expressing W12 cells. However, we did not see any evidence
of hypermutation in the HPV16 LCR in these transfectants (data
not shown). To establish another 3D-PCR assay, we chose the E2
gene. Importantly, mutation in the E2 gene may impair E2 gene
functions, which is considered to be associated with progression of
HPV-associated carcinogenesis. Moreover, the E2 gene is fre-
quently found as a boundary sequence in integrated viral DNA
(21, 24, 25, 50). In the first trial of the E2 3D-PCR assay, the
A3-estrogen receptor (ER) fusion proteins were expressed in W12
cells as an inactive form, and then A3-ER proteins were activated
by addition of an ER ligand, 4-hydroxytamoxifen (OHT) (51).
The E2 genes from the A3A and A3G transfectants were amplified
at a slightly lower denaturation temperature (85.6°C) than those
from mock transfectants (86.0°C) and a negative-control DNA
(n.c.) carrying no mutations (86.4°C) (Fig. 2A). Western blot re-
sults confirmed transgene expression levels (Fig. 2B). DNAs am-
plified at 85.6°C as shown in Fig. 2A were cloned into a T vector,
and DNA sequence was determined. Results indicated that A3A
and A3G induce low levels of hypermutation in the E2 gene (Fig.
2C and D).
Since the predominance of uracil DNA glycosylase (UNG) ac-
tivity over cytidine deaminase activity may mask a hypermutation
event, we utilized an inducible inhibition system of cellular UNG.
We controlled UNG activity by expression of the UNG inhibitor
protein (UGI). UGI is an irreversible inhibitor that forms an ex-










a F, forward; R, reverse.
FIG 1 IFN- induces APOBEC3 expression in W12 cells. (A) Expression
levels of A3s in untreated W12 cells. Quantitative PCR (qPCR) was performed
with primers to detect A3s using cDNA synthesized from transcripts derived
from untreated W12 cells and control plasmids containing DNA from each A3
protein. Using standard curves for each A3 protein, copy number was deter-
mined. The relative expression level of A3F was defined as 1. qPCR did not
detect significant expression of AID and APOBEC1 in W12 cells. (B) Expres-
sion of A3 genes at 9 and 24 h of IFN- (1,000 U/ml) stimulation was com-
pared with that of untreated W12 cells. Expression of untreated W12 cells was
defined as 1, and expression of treated cells was described as a fold change
relative to untreated cells. (C) A3G protein expression in IFN- (1,000 U/ml)-
treated W12 cells for 3 days was determined by Western blotting. Anti-
GAPDH was used as a loading control. , anti. (D) RT-PCR of ISG54 and -56
was performed using RNA identical to that used for panel B.
Wang et al.
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ceptionally stable complex with the UNG protein (37, 44). We
generated a W12 cell line that stably expresses the UGI-ER fusion
protein (Fig. 3A). We had previously demonstrated that addition
of OHT to the culture medium activated inhibitory activity of the
UGI-ER protein (37, 44). As shown in Fig. 3B, our UNG assay
revealed that OHT stimulation of UGI-ER resulted in inhibition
of UNG activity in W12 cells, although we observed residual UNG
activity (16% to 0.5% of nontransfectants) in the lysate from UGI-
activated W12 cells. Addition of OHT to parental W12 cells did
not change UNG activity, indicating that OHT did not directly
affect UNG activity (Fig. 3B, left).
The UGI-ER transfectants were then transiently transfected
with FLAG-tagged A3A, A3F, or A3G expression vectors (or green
fluorescent protein [GFP] as a negative control), and these trans-
fectants were divided into OHT-stimulated and nonstimulated
(EtOH) groups. Three days after transfection, total DNA was iso-
lated, and E2 hypermutation was examined using the E2 3D-PCR
assay. A control DNA (n.c.) carrying no mutations showed ampli-
fication with a denaturation temperature of up to 86.5°C (Fig.
3C). Another control DNA, carrying 4 C-to-T mutations (4
p.c.), showed amplification at up to 86.0°C. Any samples derived
from W12 cells, regardless of the transgene expressed, amplified
the E2 gene at 86.0°C (Fig. 3C), indicating the presence of the E2
gene with around 4 C-to-T mutations in all the transfected sam-
ples. Endogenous APOBEC3 proteins may be responsible for this
background level (86.0°C) of hypermutation and may also be re-
sponsible for spontaneous cytosine deamination that occurs in
mammalian genomic DNA (52). When A3A and A3G were ex-
pressed, we observed E2 amplification at a markedly lower dena-
turing temperature in the presence of UNG inhibition (Fig. 3C,
OHT). A3A-expressing, UNG-inhibited W12 cells produced E2
gene amplification at up to 82.6°C, which is an equivalent temper-
ature for amplification of a positive-control DNA carrying 26 C-
to-T hypermutations. Of note, a mutant A3G (mutA3G) of
deaminase active sites (E67Q/E259Q) (53) showed the same pro-
file of amplification temperature with the GFP and EtOH con-
trols, suggesting dependence on deaminase activity for hypermu-
tation, as observed in A3G-expressing, UNG-inhibited W12 cells.
To confirm E2 hypermutation, amplified E2 fragments (Fig. 3C,
boxes) were excised and cloned into a T vector. Eight Escherichia
coli clones were randomly picked up, followed by plasmid isola-
tion and sequence determination of the amplified E2 fragments.
Sequence analysis revealed robust C-to-T and G-to-A hypermu-
tations in the A3A- and A3G-expressing samples (Fig. 3D). The
positive strand of E2 3D-PCR target DNA (165 bp) contains 21
CpC and 8 TpC dinucleotides, whereas the negative strand con-
tains 5 CpC and 13 TpC dinucleotides. It has been reported that
A3A and A3G prefer T/CpC and CpC dinucleotide contexts, re-
spectively (16, 32), and this is favored by our dinucleotide context
analysis (Fig. 3E). Although the precise mechanism by which A3G
causes a C-to-T-biased hypermutation is currently unknown, the
biased distribution of the CpC dinucleotide context may partly
account for it (Fig. 3D). OHT stimulation did not change the
expression levels of A3A, A3G, and GFP (Fig. 3F). These results
clearly demonstrate that overexpression of A3A and A3G induces
hypermutation in the E2 gene, whereas UNG decreases the E2
hypermutation.
In addition, we tried to determine the overall mutation fre-
quency of the E2 hypermutation. The first PCR product for E2
3D-PCR amplified from the same DNA sample that exhibited ro-
bust hypermutation by A3A (Fig. 3C) was cloned into the T vector,
and the DNA sequence was subsequently determined. However,
we saw no significant mutations among 50 clones (262 bp  50)
over background mutation due to Taq polymerase error (data not
shown). This means that the majority of viral clones did not accu-
mulate hypermutation in the E2 gene although the highly sensitive
assay (3D-PCR) detected robust hypermutation in the same sam-
ples (Fig. 3C and D).
Detection of E2 hypermutation in the UNG-inhibited W12
cells encouraged us to further examine LCR hypermutation, using
the same protocol of LCR 3D-PCR previously reported by Varta-
nian et al. (31). We examined the hypermutation load on the LCR
in the identical samples used to detect E2 hypermutation (Fig.
3C). The LCR 3D-PCR clearly amplified a positive-control DNA,
carrying 17 C-to-T mutations (17 p.c.), at a denaturation tem-
perature of up to 79.4°C (Fig. 4A), whereas samples isolated from
any transfectants except the A3A sample showed amplification
FIG 2 Expression of A3A and A3G induces hypermutation of the E2 gene in
W12 cells. (A) A3A-, A3G-, and mock-ER proteins were expressed in W12
cells. Transfectants were cultured in the presence of 1 M OHT for 36 h, and
total DNA was subjected to E2 3D-PCR assays. A3A- and A3G-ER transfec-
tants showed amplification at a denaturation temperature (85.6°C), slightly
lower than those of the mock-ER transfectants (86.0°C) and control DNA
(86.4°C). Arrows indicate the position of 3D-PCR products (213 bp). Nega-
tive-control (n.c.) DNA carrying no mutations was also examined. (B) Expres-
sion of mock-, A3A-, and A3G-ER proteins was verified by Western blotting.
GAPDH served as a loading control. (C and D) E2 DNA amplified at a dena-
turation temperature of 85.6°C was excised, cloned, and sequenced. Results are
shown as mutation matrices (C) and alignments (D). C-to-T and G-to-A hy-
permutations are indicated as red and green vertical lines, respectively. All
other base substitutions are shown as black vertical lines. The number of C-
to-T and G-to-A conversions in each sequence is indicated. nt, nucleotides.
Interferon-Mediated E2 Gene Hypermutation in HPV16
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similar to that of the negative-control DNA, which carried no
mutations. LCR DNA of the A3A sample amplified at 80.8°C (Fig.
4A, box) was excised and cloned in T vector, and subsequent DNA
sequencing confirmed hypermutation (Fig. 4B and C). Dinucle-
otide context analysis of C-to-T mutations shows a TpC prefer-
ence that is consistent with previous reports of A3A dinucleotide
preference (Fig. 4D) (32, 54).
Suspene et al. and Mussil et al. (39, 54) demonstrated that A3A
hypermutates host nuclear gene loci such as TP53 and c-myc in
activated T cells and UGI-expressing 293T cells. Because robust E2
hypermutation was detected in the A3A- and UGI-expressing
W12 cells (Fig. 3C), we examined hypermutation in the TP53
locus using the same DNA samples as those described in Fig. 3, 4A,
and 5A. As shown in Fig. 4E, TP53 3D-PCR differentially ampli-
fied wild-type control DNA and one containing four C-to-T mu-
tations. However, neither A3-dependent nor IFN--dependent
FIG 3 A3A and A3G heavily hypermutate the E2 gene in the UNG-inhibited W12 cells. (A) Protein expression in stable UGI-ER transfectants was confirmed by
Western blotting. (B) Uracil excision activity was measured using a UNG assay with a synthetic single-stranded DNA containing a single dU. Parental and
UGI-ER-expressing W12 cells were treated with either 1 M OHT or the same amount of solvent (EtOH) for 48 h, and UNG activity was measured. Synthetic
oligonucleotides (substrate, 31-mer, and control, 15-mer) were also electrophoresed as size markers. On the right side, UNG activity of serial dilutions of nuclear
extracts was determined. The percent density of signals for the 15-mer is indicated. Signal density of the EtOH-treated UGI-ER-expressing W12 cells was defined
as 100%. OHT stimulation decreased UNG activity in the UGI-ER transfectants. The asterisk represents an abasic site. On the left, uracil excision activity of
parental W12 cells was compared. (C) Expression vectors of the indicated proteins were used to transfect UGI-ER transfectants. Twenty-four hours after
transfection, 1M OHT (or EtOH) was added to activate the UGI-ER protein. After a further 72 h of incubation, total DNA was purified, and E2 3D-PCR assays
were performed. Plasmids containing the E2 gene fragments carrying no (n.c.), 4 (4p.c.), or 26 (26p.c.) C-to-T mutations were simultaneously amplified and
served as controls. Expression of A3A and A3G induced robust hypermutation in UNG-inhibited W12 cells. Arrows indicate the positions of E2 3D-PCR
products (213 bp). (D and E) Summary of 3D-PCR amplicon sequences recovered from the work shown in panel C. Boxed PCR fragments described in panel C
were excised and cloned into a T vector, and 8 randomly selected clones were sequenced. Results were shown as mutation matrices (D, left), alignments (D, right),
and 5=-dinucleotide context analysis (E). *, P  0.05; **, P  0.01. The reference sequence (GenBank accession number AF125673.1) was used to identify
mutations. (F) The levels of expressed proteins described in panel C were determined by Western blotting using the indicated antibodies. HA, hemagglutinin.
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hypermutation was detected. Regardless of transgene expression
or stimulation, all W12 samples showed amplification of TP53 at
the same level as the DNA containing four C-to-T mutations (Fig.
4E), suggesting that the background mutations are present in W12
cells. Results obtained from 3D-PCR of E2, LCR, andTP53 suggest
that A3s may selectively hypermutate viral DNA in W12 cells and
that E2 hypermutation may involve a mechanism other than the
proposed catabolic hypermutation (39).
IFN- initiates E2 hypermutation through APOBEC3 ex-
pression. Since overexpression of A3A and A3G induced E2 hy-
permutation in UNG-inhibited W12 cells (Fig. 3) and IFN- up-
regulated expression of A3s (Fig. 1B), we next examined whether
endogenous A3A and A3G cause E2 hypermutation. The UGI-ER
transfectants were cultured in the presence of IFN- and OHT,
and E2 hypermutation was examined by the E2 3D-PCR assays.
3D-PCR of the IFN--treated samples showed clear but modest
amplification of the E2 gene at a denaturation temperature
(84.6°C) lower than that of the negative-control DNA (86.5°C)
and the IFN--untreated sample (86.5°C), indicating induction of
E2 hypermutation by IFN- in the UNG-inhibited W12 cells (Fig.
5A). DNA sequencing of the E2 fragments revealed C-to-T hyper-
mutation (Fig. 5B, open box). Dinucleotide context analysis of
IFN--mediated hypermutation showed CpC as a most frequent
mutated dinucleotide (Fig. 5C), consistent with dinucleotide pref-
erences of A3G (16, 32). To assess the contribution of A3A and
A3G in IFN--mediated hypermutation, we transfected siRNAs
against A3A and A3G and then stimulated UGI-ER transfectants
with IFN- in the presence of OHT. RT-qPCR revealed that trans-
fection of siRNAs against A3A (siA3A) and A3G suppressed
mRNA levels of A3A and A3G at half and 60% of that in the
control siRNA (siCont) transfection, respectively (Fig. 5D). West-
ern blotting reconfirmed the reduction of A3G protein levels in
siA3G-transfected samples (Fig. 5E). As shown in Fig. 5F, trans-
fection of siCont, followed by stimulation with IFN-, resulted in
amplification of E2 DNA at lower denaturation temperatures
(83.2 and 82.6°C) than n.c. (86.5°C), whereas transfection of
siA3G resulted in an increase in the denaturation temperature
(85.3°C). Transfection of siA3A resulted in amplification of the E2
gene at denaturation temperatures (83.2 and 83.9°C) slightly
higher than those of siCont. Sequences of amplified DNAs at de-
naturation temperature lower than 86.0°C in Fig. 5F were deter-
mined. The results showed that E2 hypermutation detected in the
siCont samples was biased toward C-to-T mutations (Fig. 5G),
similar to the result shown in Fig. 5B. Hypermutation detected in
the siA3G-transfected samples was biased toward the G-to-A mu-
tations (Fig. 5G). Dinucleotide context analysis showed that
knockdown of A3G decreased CpC and increased TpC dinucle-
otide contexts in comparison with that of siCont (Fig. 5H). These
results collectively suggest that endogenous A3G contributes to E2
hypermutation following IFN- stimulation in W12 cells. Mean-
while, the contribution of endogenous A3A may be minor judging
by the results of dinucleotide context analysis, knockdown exper-
iments, and its expression level (Fig. 1A, 3, and 5).
Expression of APOBEC3 proteins does not affect episomal
HPV16 DNA levels in W12 cells. It has been previously reported
that IFN- downregulates the viral episome level in HPV-positive
keratinocytes, including W12 cells (35, 45). To evaluate whether
A3s are involved in the reduction of viral DNA by IFN-, the level
of viral DNA was measured by Southern blotting. First, W12 cells
were transfected with A3A, A3G (and its mutant), and control
(GFP) expression vectors, and 3 days after transfection, total DNA
was subjected to Southern blotting. Transfection conditions were
exactly the same as those used for observation of A3A- and A3G-
dependent hypermutation, as shown in Fig. 3. As shown in Fig.
6A, we observed no obvious reduction in HPV episome levels by
overexpression of A3A and A3G. Western blotting was performed
to determine transgene expression levels (Fig. 6A, bottom panels).
A3s are proposed to degrade HIV-1 viral DNA through the
UNG-initiating BER pathway (2, 16, 55). We determined whether
UNG inhibition interferes with the IFN--mediated downregula-
tion of viral DNA using UGI-ER transfectants. After 3 days of
stimulation with IFN- and OHT, as indicated in Fig. 6B, total
DNA was recovered, and HPV16 DNA levels were determined.
Stimulation with 1,000 U/ml IFN- for 3 days slightly reduced
HPV16 DNA levels; however, this reduction was not markedly
affected by UNG inhibition (Fig. 6B, lane 3 versus lane 4). These
FIG 4 A3A expression causes LCR hypermutation in UGI-ER transfectants. (A) The total DNA samples used in Fig. 3C and 5A were analyzed in the LCR 3D-PCR
assay. Control LCR 3D-PCRs were simultaneously carried out with the indicated control DNAs (n.c. and 17 p.c.); 17 p.c. and n.c. carry 17 C-to-T and no
mutations in LCR DNA, respectively. The A3A-expressing sample showed a faint signal amplified at a denaturation temperature of 80.8°C (indicated by the open
box). (B to D) The PCR signal indicated by the open box was cloned and sequenced. Results are shown as mutation matrices in panel B, alignments in panel C,
and 5=-dinucleotide context analysis in panel D. (E) The same samples shown in panel A were also examined by TP53 3D-PCR assay. Control DNAs carrying no
mutations (n.c.) and four C-to-T mutations (4 p.c.) were used simultaneously.
Interferon-Mediated E2 Gene Hypermutation in HPV16
January 2014 Volume 88 Number 2 jvi.asm.org 1313
 o
n







data suggest that A3s and UNG do not contribute to a reduction in
viral DNA by IFN- treatment at least under the experimental
condition used in this study.
DISCUSSION
A3s are IFN-inducible proteins that restrict reverse transcription-
dependent viruses and retrotransposable elements by binding the
viral RNP complex, hypermutating nascent DNA, and inhibiting
reverse transcription and viral DNA integration (1, 2, 14–16).
Vartanian et al. clearly demonstrated that precancerous cervical
biopsy samples contain hypermutated HPV DNA (31). However,
it has not been shown whether A3 expression is induced in human
cervical keratinocytes by IFN stimulation or whether the hyper-
mutated DNA is derived from infected cervical keratinocytes. In
FIG 5 Endogenous APOBEC3 proteins hypermutate E2 in UNG-inhibited W12 cells. (A) UGI-ER transfectants were treated with 1,000 U/ml IFN- (or were
untreated) and 1 M OHT. After 72 h of incubation, the cells were harvested, and E2 3D-PCR was performed. (B and C) Boxed PCR fragments shown in panel
A were excised and cloned into a T vector, and 6 randomly selected clones were sequenced. Detected mutations are shown in panel B, 5=-dinucleotide context
analysis is shown in panel C, top, and alignments are shown in panel C, bottom. (D to H) UGI-ER transfectants were transfected with A3A- or A3G-specific (or
control) siRNA, and at 6 h after transfection, the cells were treated with 1,000 U/ml IFN- and 1M OHT. After a further 48 h of incubation, cells were harvested
and analyzed. (D) Knockdown efficiency for siA3As and siA3Gs and their target specificity. RT-qPCR was performed to measure knockdown efficiency and
specificity of siA3A and siA3G transfections. A3 expression levels were normalized to that of HPRT1. The expression level of siCont transfectants was defined as
1. (E) Knockdown efficiency of siA3G was determined by Western blotting. Cell lysate derived from nontagged A3G-transfected 293T cells served as a control.
(F) 3D-PCR assay of E2. Total DNA was extracted from siCont-, siA3A-, and siA3G-transfected UGI-ER transfectants was subjected to E2 3D-PCR. (G and H)
PCR products amplified at less than 86.0°C, as shown in panel F, were excised and cloned. (G) Results are summarized using alignments. C-to-T and G-to-A
hypermutations are indicated as red and green vertical lines, respectively. All other base substitutions are shown as black vertical lines. The number of C-to-T or
G-to-A conversions in each sequence is indicated. 5=-dinucleotide context analysis was also performed, as shown in panel H. *, P  0.05; **, P  0.01. n.c.,
negative-control DNA carrying no mutations. 26 p.c., DNA carrying 26 C-to-T mutations.
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the present study using W12 cells, an in vitro model for analyzing
the early phase of natural HPV16 infection, we investigated
whether A3s can hypermutate HPV16 episomal DNA. IFN-
treatment of W12 cells resulted in the upregulation of A3A and
A3G mRNA levels and induction of hypermutation in HPV16
DNA (Fig. 1B and 5). Exogenous expression of A3A and A3G
induced hypermutation (Fig. 2, 3, and 4), whereas knockdown of
endogenous A3A and A3G reduced the hypermutation induced by
IFN- treatment (Fig. 5F). These results suggest that A3G and
A3A are responsible for IFN--induced E2 hypermutation. How-
ever, these hypermutation events are rare because hypermutation
can be detected only after enrichment by 3D-PCR (data not
shown). Southern blotting of viral DNA did not show reduction of
viral replication in A3A- and A3G-expressed W12 cells. In the case
of HBV, hypermutation was detected in A3G-expressing hepato-
cytes even without 3D-PCR, and reduction in HBV viral DNA
levels was observed in A3G-overexpressed samples (37). It is pos-
sible that hypermutation by A3s may not be sufficiently extensive
to cause reduction of viral DNA in W12 cells. A series of in vitro
studies using purified A3 proteins revealed single-stranded DNA
to be an efficient target for A3s (1, 2, 14). We speculate that HPV
episomes may not expose a sufficient single-stranded DNA region,
and accordingly, poor accessibility of A3s to viral DNA may ac-
count for the insufficient accumulation of hypermutations re-
quired for antiviral activity of A3s against HPV16. It is also possi-
ble that HPV16 has a yet unknown mechanism that inhibits A3
antiviral activity. It is well established that HIV-1 counteracts A3
antiviral activity by a viral protein, Vif (2, 14). Because W12 is an
established cell line that stably maintains episomal DNA, it is pos-
sible that the virus in this cell line may have overcome the effect of
antiviral activities initiated by naive epithelial cells shortly after
infection.
Integration of viral DNA into the host genome is an important
step in HPV-associated carcinogenesis, and E2 is frequently found
disrupted in invasive cervical cancer through viral DNA integra-
tion (24, 25). Because the HPV genome does not encode integrase
or recombinase that supports viral DNA integration, both viral
and cellular DNA need to be cleaved at least once by cellular fac-
tors prior to integration. It was previously shown that IFN- treat-
ment of W12 cells induces clearance of HPV16 episomes from cell
populations and facilitates the emergence of cell clones harboring
integrated HPV16 DNA (35), suggesting that such DNA cleavages
may be induced following IFN- stimulation. Interestingly, our
data demonstrate that IFN- treatment of W12 cells results in the
accumulation of C-to-U conversions in the E2 gene through the
deaminase activity of A3s (Fig. 5A and B). Moreover, we showed
that UGI enabled an increase in detectable C-to-U conversion
generated by A3s (Fig. 3C). Uracil bases in Ig genes generated by
AID are converted into DNA double-strand breaks through the
UNG-mediated BER pathway, and the resulting DNA ends are
resolved as class switch recombination, gene conversion, and
chromosomal translocation (3, 4, 6). We analogously speculate
that uracil bases in the E2 gene generated by A3s may result in
DNA strand breaks, leading to viral DNA integration. More-
over, it was recently reported that A3A and A3B expression
induces DNA double-strand breaks and genomic instability
(13, 54, 56). DNA strand breaks in viral DNA and host genomic
DNA may synergistically increase the chance of viral DNA in-
tegration. Although E2 hypermutation is an infrequent event in
W12 cells, if this could induce viral DNA integration, it would
have a significant impact on facilitating oncogenesis because
enhanced expression of E6 and E7 oncogenes from the E2-
disrupted integrated HPV genome may transform keratino-
cytes and give them growth advantage in the cell population
(22, 25, 50).
Another potential role of A3s in HPV-related oncogenesis is as
a source of mutations. Human cancers, including cervical cancer,
have a novel form of mutation (called kataegis), in which C-to-T
mutations are clustered in a small genomic region (11, 12). A3A
and A3B introduce these kataegis mutations (8–10, 13). In the
present study, we demonstrated that A3A expression is induced by
IFN- stimulation and that A3A induces E2 hypermutation in
W12 cells (Fig. 1 and 5). Although we did not detect A3A-depen-
dent TP53 hypermutations, it is possible for A3A to mutate other
genomic regions and to play a mutagenic role in HPV-related
oncogenesis. Further studies are required to elucidate the role of
A3s in HPV-related oncogenesis.
FIG 6 A3G and A3A expression did not change episomal DNA levels in W12
cells. Episomal DNA levels were examined by Southern blotting. (A) W12 cells
were transfected with the indicated expression vectors, and 72 h after transfec-
tion, total DNA was recovered and digested with BamHI, which cuts once in
HPV16 episomal DNA. Fifteen micrograms of the digested total DNA was
loaded per lane. The top panel represents linearized HPV16 (7.9 kb), and the
second panel shows the loading control by blotting for a particular cellular
gene locus. A3A and A3G expression did not change the viral load in the W12
cells. Expression levels of GFP, A3A, and A3G are shown by Western blotting
(bottom panels). (B) UGI-ER transfectants were treated with 1 M OHT and
1,000 U/ml IFN-, as indicated, and were cultivated for 72 h. Southern blot-
ting was performed as described for panel A. Signal intensities of HPV16 DNA
from three independent experiments were normalized to that of the loading
control and are indicated at the bottom. The signal in lane 1 (most left line) is
defined as 1. **, P 0.01.
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